Premium
First experience of the AML‐Berlin‐Frankfurt‐Münster group in pediatric patients with standard‐risk acute promyelocytic leukemia treated with arsenic trioxide and all‐ trans retinoid acid
Author(s) -
Creutzig Ursula,
Dworzak Michael N.,
Bochennek Konrad,
Faber Jörg,
Flotho Christian,
Graf Norbert,
Kontny Udo,
Rossig Claudia,
Schmid Irene,
Stackelberg Arend,
Mueller JansEnno,
Neuhoff Christine,
Reinhardt Dirk,
Neuhoff Nils
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26461
Subject(s) - arsenic trioxide , medicine , acute promyelocytic leukemia , leukemia , retinoid , tretinoin , gastroenterology , pediatrics , surgery , arsenic , retinoic acid , biochemistry , materials science , chemistry , metallurgy , gene
Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low‐risk patients treated with all‐ trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low‐risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.